<DOC>
	<DOCNO>NCT00156793</DOCNO>
	<brief_summary>This study design evaluate ability AI-700-enhanced rest-stress echocardiography detect coronary artery disease ( CAD ) patient suspect ischemic heart disease indicate single-photon emission compute tomography ( SPECT ) imaging .</brief_summary>
	<brief_title>Phase 3 Imaging Safety Study AI-700 Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging</brief_title>
	<detailed_description>Assessment myocardial perfusion demonstrate provide diagnostic prognostic value patient ischemic heart disease allow clinician ass hemodynamic significance coronary artery disease ( CAD ) . The primary objective clinical development program AI-700 demonstrate safety efficacy AI-700 intravenous ultrasound contrast agent patient suspect myocardial perfusion defect . The patient population comprise patient evaluate inducible ischemia . The primary study objective determine accuracy , sensitivity , specificity AI-700-enhanced echocardiographic image detect CAD use coronary angiography/left ventriculography ( ANGIO/LVG ) single-photon emission compute tomography ( SPECT ) clinical outcome reference standard .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Men nonpregnant/nonlactating woman recent history typical atypical chest pain ( angina ) 18 80 year age clinically indicate SPECT evaluation presence inducible ischemia enrol . Study candidate follow condition exclude study : clinically unstable condition major surgery within 7 day prior AI700 dosing ; acute MI , cerebrovascular accident transient ischemic attack within 30 day prior dose ; congestive heart failure grade New York Heart Association Grade 4 within 3 month prior dose ; significant leave main CAD ; moderate severe chronic obstructive pulmonary disease ; oxygen saturation &lt; 90 % rest ; prior CABG ( unless &gt; = 6 month prior AI700 dose patient typical angina ) Candidates significant cardiovascular pulmonary structural and/or functional abnormality , visualization leave ventricle adequate evaluation cardiac function Exclusion ECHO , eligible participate study . Patients history MI nonCAD etiology exhibit new change ECG abnormality time Screening AI700 dose similarly exclude . Other exclusion criterion include : participation investigational drug/device study within 30 day prior dose ( 90 day UK site ) , nonseasonal asthma within past 3 year recent seasonal asthma require prescription medication , organ transplant endstage organ failure , active seizure disorder . Candidates exclude uncontrolled atrial fibrillation , frequent premature ventricular atrial contraction , history prolong QT/QTc , use automatic implantable cardioverter/defibrillator pacemaker , rhythm abnormality evaluate treated specialist current treatment ensure patient safety . Candidates use methylated xanthine within 24 hour dose also exclude . Patients also exclude aminophylline , theophylline , dipyridamole contraindicate accord agent â€™ product labeling .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>ischemia</keyword>
	<keyword>echocardiography</keyword>
	<keyword>cardiac imaging</keyword>
	<keyword>heart disease</keyword>
	<keyword>myocardial contrast enhancement</keyword>
	<keyword>myocardial perfusion</keyword>
	<keyword>wall motion</keyword>
	<keyword>ultrasound contrast agent</keyword>
</DOC>